Pay in 4 interest-free payments of $5.88 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
About 70% of American adults are either overweight or actually obese
These benefits have been observed when GLP-1 RAs are used as add-on therapy to oral hypoglycemic agents or in combination with basal insulin, as evidenced by several recent studies (Yang et al., 2020)
Eligible plan types exclude Defined Standard benefit plans, which charge a standard 25% coinsurance amount for all covered drugs and do not vary cost sharing by drug type or formulary tier, although plan sponsors could indicate if they wished to convert a Defined Standard benefit plan to another basic benefit type in order to become eligible
Challenges: Despite this strong market position, Novo faces significant challenges
The benefit matters only when the platform shows licensed review and a path to in-person care
Mantovani A, Byrne CD, Targher G (2022) Efficacy of peroxisome proliferator-activated receptor agonists, glucagon-like peptide-1 receptor agonists, or sodium-glucose cotransporter-2 inhibitors for treatment of non-alcoholic fatty liver disease: a systematic review
US$ 21.75
US$ 21.65
US$ 23.21
US$ 27.51
